Timm’s stain under different treatments in the CA3.

<p>(A) The Timm’s score was significantly increased after SE induction. MK-801 and lovastatin significantly decreased Timm’s score after SE induction. Scale bar, 200 µm in the left panels and 100 µm for the right panels. (B) Summary data showing the mean Timm’s score between control and experimental groups in the CA3. (*compared with control group; #compared with SE group).</p

Nissl stain under different treatments in the DG.

<p>(A) After SE, the thickness of granule cell layer was significant increased. After SE induction, MK-801 significantly decreased the thickness of granule cell layer but lovastatin did not. Scale bar, 100 µm. (B) Summary data showing the mean thickness of granule cell layer between control and experimental groups in the DG. (*compared with control group; #compared with SE group).</p

DataSheet_1_The Autonomic Progress Bar Motivates Treatment Completion for Patients of Stimulant Use Disorder and Cannabis Use Disorder.docx

Background: The intrinsic motivation behind the “need to complete” is more influential than external incentives. We introduced a novel progress-bar tool to motivate the completion of programs designed to treat stimulant and cannabis use disorders. We further examined the effectiveness of the progress bar's scoring approach in forecasting consistently negative urine tests.Methods: This study's participants included 568 patients with stimulant, amphetamine-type, and cannabis use disorders who were undergoing 12-month mandatory treatment programs at Taichung Veterans General Hospital in Taiwan. Patients were given scores of 1, -1, or 0 depending on whether they received negative, positive, or missing urinalysis reports, respectively. The autonomic progress bar generated weekly score totals. At the group level, scorei donated scores from all patients for a given week (i denoted the week). Scorei was standardized to adjusted scorei. We then conducted Autoregressive Integrated Moving Average (ARIMA) Model of time-series analyses for the adjusted scorei.Results: A total of 312 patients maintained treatment progress over the 12-month program. The autonomic score calculator totaled the shared achievements of these patients. The coefficients of the lag variables for mean (p), lag variables for residual error term (q), and number of orders for ensuring stationary (d) were estimated at p = 3, d = 4, and q = 7 for the first half of the treatment program, and were estimated at p = 2, d = 2, and q = 3 for the second half. Both models were stationary and tested as fit for prediction (p Discussion: This study's novel progress-bar tool effectively motivated treatment completion. It was also effective in forecasting continually negative urine tests. The tool's free open-source code makes it easy to implement among many substance-treatment services.</p

Lovastatin significantly alter the expression and phosphorylation pattern of GSK-3β at day 3 and 7 after pilocarpine-induced SE.

<p>The GSK-3β protein expression and phosphorylation levels from control, SE and SE+statin rat hippocampus was determined by western blot. pGSK-3β indicate the serine phosphorylation of GSK-3β. GAPDH was used as loading control. Lower panel show quantification of the relative protein amount of GSK-3β and serine phosphorylation level of GSK-3β. (A) The expression level of GSK-3β at day 3 after SE. (B) The expression level of GSK-3β at day 7 after SE. (*compared with control group; #compared with SE group).</p

Drug administration regimen.

<p>All the drugs were injected subcutaneously after SE induction.</p

Lovastatin significantly alter the expression pattern of CRMP-2 at day 3 and day 7 after pilocarpine-induced SE.

<p>The CRMP-2 protein expression levels from control, SE and SE+statin was determined by western blot. GAPDH was used as loading control. Lower panel show quantification of the relative protein amount of CRMP-2. (*compared with control group; #compared with SE group).</p

The effect of lovastatin on the eEPSC_NMDA.

<p>(A) The eEPSC_NMDA was not significantly altered by lovatstatin (100 µM) application. Scale bar, 20 ms, 100 pA. (B) Summary data showing the mean amplitude of the eEPSC_NMDA between control and experimental groups in the DG.</p

The experimental design and Timm’s score recorded from different time points.

<p>(A) The experimental design of TLE animal model and drug administration. (B) Timm’s score recorded from control and 1 to 3 months after SE induction. 1 month after SE induction, the Timm’s score was significantly increased compared with control group and show an increasing tendency with time. (*compared with control group).</p

The expression frequency of immunophenotypes in patients with enterovirus 71 infection by disease severity.

<p>The expression frequency of CD4⁻CD8⁻, CD4⁺Foxp3⁺ and CD4⁺CD25⁺Foxp3⁺ decreased markedly in patients with autonomic nervous system dysregulation or pulmonary edema, *<i>P</i><.05.</p

The expression of CD4⁺Foxp3⁺ and cytokine profile in patient with ANS dysregulation or pulmonary edema by milrinone treatment.

<p>The expression frequency of CD4⁺Foxp3⁺ increased and plasma cytokine levels of IL-6, IL-8 and IL-10 decreased after milrinone treatment. *<i>P</i><.01.</p